8-K: Current report filing
Published on September 23, 2014
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________________________________________________________________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 19, 2014
_________________________________________________________________________________
AETHLON MEDICAL, INC.
(Exact name of registrant as specified in its charter)
|
Nevada (State or other jurisdiction of incorporation) |
000-21846 (Commission File Number) |
13-3632859 (I.R.S. Employer Identification No.) |
|
8910 University Center Lane, Suite 660 San Diego, California (Address of principal executive offices) |
92122 (Zip Code) |
Registrant’s telephone number, including area code: (858) 459-7800
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01 Regulation FD Disclosure
The Registrant disclosed that on Friday, September 19, 2014, it made a presentation at the 2014 Exosomes & SingleCell Analysis Summit in San Diego, California. A copy of the presentation materials are being furnished as an exhibit to this report and are incorporated by reference into this Item 7.01. Also, the Registrant posted the presentation materials to its website (www.aethlonmedical.com) today, September 23, 2014.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits. The following exhibit is being furnished pursuant to Item 7.01 above.
| Exhibit No. | Description | ||
| 99.1 | Aethlon Exosome & SingleCell Analysis Summit Presentation 09-19-14 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| AETHLON MEDICAL, INC. | ||
| (Registrant) | ||
| Date: September 23, 2014 | By: | /s/ James B. Frakes |
| James B. Frakes | ||
| Chief Financial Officer | ||
EXHIBIT INDEX
| Exhibit No. | Description | |
| 99.1 | Presentation Materials |